Pfizer 2009 Annual Report Download - page 90

Download and view the complete annual report

Please find page 90 of the 2009 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 110

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
The following summarizes all TSRU activity during 2009:
SHARES
(THOUSANDS)
WEIGHTED-
AVERAGE GRANT
DATE VALUE
PER SHARE
Nonvested, December 31, 2008 2,756 $22.49
Granted 6,365 14.62
Vested (47) 18.02
Forfeited (393) 16.12
Nonvested, December 31, 2009 8,681 17.04
The following table provides data related to all TSRU activity:
YEAR ENDED DECEMBER 31,
(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS AND YEARS) 2009 2008
Weighted-average grant date fair value per TSRU $4.26 $5.54
Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax $23 $9
Weighted-average period in years over which TSRU cost is expected to be recognized 2.1 2.2
16. Earnings per Common Share
Basic and diluted EPS were computed using the following common share data:
YEAR ENDED DECEMBER 31,
(IN MILLIONS) 2009 2008 2007
EPS Numerator—Basic:
Income from continuing operations attributable to Pfizer Inc. $8,621 $8,026 $8,213
Less: Preferred stock dividends—net of tax 234
Income from continuing operations attributable to Pfizer Inc. common shareholders 8,619 8,023 8,209
Discontinued operations—net of tax 14 78 (69)
Net income attributable to Pfizer Inc. common shareholders $8,633 $8,101 $8,140
EPS Denominator—Basic:
Weighted-average number of common shares outstanding 7,007 6,727 6,917
EPS Numerator—Diluted:
Income from continuing operations attributable to Pfizer Inc. $8,621 $8,026 $8,213
Less: ESOP contribution—net of tax ——2
Income from continuing operations attributable to Pfizer Inc. common shareholders 8,621 8,026 8,211
Discontinued operations—net of tax 14 78 (69)
Net income attributable to Pfizer Inc. common shareholders $8,635 $8,104 $8,142
EPS Denominator—Diluted:
Weighted-average number of common shares outstanding 7,007 6,727 6,917
Common-share equivalents—stock options, stock issuable under employee compensation
plans and convertible preferred stock 38 23 22
Weighted-average number of common shares outstanding and common-share
equivalents 7,045 6,750 6,939
Stock options that had exercise prices greater than the average market price of our
common stock issuable under employee compensation plans(a) 400 489 514
(a) These common stock equivalents were outstanding during 2009, 2008 and 2007 but were not included in the computation of diluted EPS for those
years because their inclusion would have had an anti-dilutive effect.
88 2009 Financial Report